CAS Investment Management has returned for a $34m series A-plus round that was led by CDH Wealth Management.
China-based drug discovery platform Zonsen Peplib Biotech has secured RMB220 ($34m) in a series A-plus round backed by CAS Investment Management, an investment firm co-founded by Chinese Academy of Sciences, according to DealStreetAsia.
CDH Wealth Management, a unit of alternative asset manager CDH Investments, led the round, which also included conglomerate Legend Holdings’ early-stage investment arm Legend Star.
ASB Ventures, Highlight Capital, Cowin Capital and Fortune Capital filled out the round.
Founded in 2017, Zonsen has developed…